Placenta-Derived Stem Cells Appear Safe in Early Trial for Progressive MS
A small Phase 1 trial of placenta-derived mesenchymal stem cells in secondary progressive MS found no serious safety concerns and noted exploratory improvements in inflammation and brain function.
